This clinical study is investigating AMG 719, an investigational drug, for the treatment of patients who have Rheumatoid Arthritis and who are taking Methotrexate. AMG 719 is a drug which is self-injected beneath the skin (similarly to the way insulin is self-injected by diabetics). Patients on this study are on study for 28-weeks. They visit the study facility at least 11 times while participating in the study.

Condition	Treatment or Intervention	Phase
Arthritis, Rheumatoid	Drug: AMG 719	Phase II

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

• Men or women, at least 18 years of age at screening
• Diagnosed with Rheumatoid Arthritis, with a disease duration of at least 24 weeks, receiving methotrexate, and having no recent history of substance or alcohol abuse

Arizona
      Research Center, Paradise Valley,  Arizona,  United States
      Research Center, Phoenix,  Arizona,  United States
California
      Research Center, San Diego,  California,  United States
      Research Center, Santa Maria,  California,  United States
Indiana
      Research Center, Indianapolis,  Indiana,  United States
Maine
      Research Center, Bangor,  Maine,  United States
Maryland
      Research Center, Hagerstown,  Maryland,  United States
      Research Center, Frederick,  Maryland,  United States
New Jersey
      Research Center, Voorhees,  New Jersey,  United States
Pennsylvania
      Research Center, Wyomissing,  Pennsylvania,  United States
      Research Center, Duncansville,  Pennsylvania,  United States
Texas
      Research Center, Dallas,  Texas,  United States

Study ID Numbers:  20010238
Record last reviewed:  October 2002
Last Updated:  October 13, 2004
Record first received:  May 29, 2002
ClinicalTrials.gov Identifier:  NCT00038298
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08